Navigation Links
Dominion Diagnostics -- The Only Specialty Urine Drug Monitoring Laboratory to Offer Quantitative Detection of Tapentadol (Nucynta(TM)) by LC/MS/MS
Date:9/14/2009

NORTH KINGSTOWN, R.I., Sept. 14 /PRNewswire/ -- Dominion Diagnostics (Dominion) has recently developed and validated one of the first clinical quantitative assays for the drug tapentadol (Nucynta(TM)) performed by liquid chromatography/tandem mass spectrometry (LC/MS/MS). Tapentadol, recently approved for use by the FDA, is a centrally-active analgesic that has demonstrated efficacy in pain relief with improved gastrointestinal tolerability compared to other opioids for pain management.

Dominion's new assay by LC/MS/MS can detect and identify the primary drug tapentadol. Tapentadol is extensively metabolized in humans. In clinical studies 97% of the administered dose was metabolized, with 70% of the dose excreted in the urine in the conjugated form (55% as tapentadol-O-glucuronide and 15% and tapentadol-O-sulfate). Tapentadol excretion is almost exclusively renal. In a clinical study, it was shown that greater than 95% of a single dose of tapentadol was excreted in the urine within 24 hours of oral administration(1).

"This is a noteworthy achievement for our Research & Development (R&D) and Laboratory Teams," stated Chief Operating Officer Stephen Jordan. "Dominion has invested considerable time and resources in developing this new tapentadol assay. Providing assays for new pain medications allows us to better support our clients' need for relevant and accurate technologies when relying on urine drug monitoring to support patient adherence."

Dominion's quantitative tapentadol assay, one of the first presented to the industry, is now available to all clients across the country. This new development comes as part of Dominion's continued commitment to unparalleled laboratory excellence. Dominion continues to lead the industry in its quest for accurate, clinically relevant science for use in appropriately monitoring chronic pain patients. Dominion's R&D team actively works with leading assay manufacturers and pharmaceutical companies to develop accurate, specific tests that meet current and future needs of the growing pain management industry.

"Our LC/MS/MS assay for tapentadol is highly sensitive and offers clinicians an accurate means of detecting tapentadol in patients that are prescribed the drug, patients that may be diverting their medications, or in other cases where a patient may have been provided the drug from other sources," Dominion's Director of Research & Development Matthew Woodcock, Ph.D. commented. "At Dominion, we recognize the important clinical implications of urine drug monitoring, and we pride ourselves on offering scientifically accurate solutions to support every clinical scenario."

Source:

(1) Terlinden R et al., Eur J Drug Metab Pharmacokinet (2007); Jul-Sep 32(3): 163-169.

Nucynta(TM) is a registered trademark of Ortho-McNeil(R), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

ABOUT DOMINION DIAGNOSTICS

Dominion Diagnostics is a premier provider of comprehensive clinical quantitative urine drug testing, medication monitoring and support services nationwide. For over 13 years, Dominion has provided services to thousands of clients in a variety of medical specialties, including Pain Medicine, Primary Care, Addiction Treatment, Behavioral Health, Psychiatry and Hospital Systems. Dominion is supported by a world-class team that shares a commitment to clinical and operational excellence. For more information about Dominion, please visit www.dominiondiagnostics.com.

    Contact:
    Julie Lenahan
    Director of Marketing
    Dominion Diagnostics
    (401) 667-0876
    jlenahan@dominiondiagnostics.com


'/>"/>
SOURCE Dominion Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dominion Diagnostics to Host Open House Reception in New Vermont Laboratory Facility
2. Dominion Helps Communities by Donating $1 Million to Health Clinics
3. Capital BlueCross Acquires Dominion Dental
4. Dominion Diagnostics Announces Launch of Comprehensive New Company Website
5. Dominion Diagnostics Supports Rhode Islands Toys for Tots Initiative at Its 2007 Holiday Celebration
6. Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
7. Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
8. Reportlinker Adds Therapeutics and Diagnostics for Womens Disorders Report
9. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
10. Quest Diagnostics Declares Quarterly Cash Dividend
11. eCardio Diagnostics Expands Corporate Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... SAN CLEMENTE, Calif. , June 24, 2016  American Respiratory ... testing company, is now able to perform sophisticated lung assessments in ... Medical Technologies , Inc. Patients are no longer ... to ndd,s EasyOne PRO ® , ARL patients like Jeanne R. ... testing done in the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, ... less invasive and more durable cerebrospinal fluid treatments, ... funding.  The Series-A funding is led by Innova ... Fund, and other private investors.  Arkis, new financing ... instrumentation and the market release of its in-licensed ...
Breaking Medicine Technology: